Breaking Barriers: Candidalysin Disrupts Epithelial Integrity and Induces Inflammation in a Gut-on-Chip Model
Toxins · 2025
DOI: 10.3390/toxins17020089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Moran Morelli und 1 weiteren Autor:innen. Beteiligte Einrichtung: MIMETAS B.V., De Limes 7, 2342 DH Oegstgeest, The Netherlands. Hauptthemen laut MEDLINE: Intestinal Mucosa, Fungal Proteins, Candida albicans, Inflammation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union Horizon 2020, Ministry of Economic Affairs and Climate Policy, Dutch National Growth Fund.
Abstract (Originalsprache)
Candida albicans is an opportunistic pathogenic yeast commonly found in the gastrointestinal tract of healthy humans. Under certain conditions, it can become invasive and cause life-threatening systemic infections. One mechanism used by C.albicans to breach the epithelial barrier is the secretion of candidalysin, a cytolytic peptide toxin. Candidalysin damages epithelial membranes and activates the innate immune response, making it key to C.albicans’ pathogenicity and a promising therapeutic target. Although candidalysin mediates C. albicans translocation through intestinal layers, its impact on epithelial responses is not fully understood. This study aims to characterize this response and develop scalable, quantitative methodologies to assess candidalysin’s toxicological effects using gut-on-chip models. We used the OrganoPlate® platform to expose Caco-2 tubules to candidalysin and evaluated their response with trans-epithelial electrical resistance (TEER), protein detection, and immunostaining. We then validated our findings in a proof-of-concept experiment using human intestinal organoid tubules. Candidalysin impaired barrier integrity, induced actin remodeling, and increased cell permeability. It also induced the release of LDH, cytokines, and the antimicrobial peptide LL37, suggesting cellular damage, inflammation, and antimicrobial activity. This study strengthens our understanding of candidalysin’s role in C. albicans pathogenesis and suggests new therapeutic strategies targeting this toxin. Moreover, patient-derived organoids show promise for capturing patient heterogeneity and developing personalized treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MIMETAS B.V., De Limes 7, 2342 DH Oegstgeest, The Netherlands.
ORCID-Profile: Moran Morelli
Förderung
- European Union Horizon 2020
- Ministry of Economic Affairs and Climate Policy
- Dutch National Growth Fund
- European Union’s Horizon 2020
- Ministry of Economic Affairs and Climate of The Netherlands
- Oncode Accelerator
Zitieren
APA
Morelli, M., & Queiroz, K. (2025). Breaking Barriers: Candidalysin Disrupts Epithelial Integrity and Induces Inflammation in a Gut-on-Chip Model. Toxins. https://doi.org/10.3390/toxins17020089
Vancouver
Morelli M, Queiroz K. Breaking Barriers: Candidalysin Disrupts Epithelial Integrity and Induces Inflammation in a Gut-on-Chip Model. Toxins. 2025. doi:10.3390/toxins17020089
BibTeX
@article{Morelli2025,
author = {Morelli, Moran and Queiroz, Karla},
title = {Breaking Barriers: Candidalysin Disrupts Epithelial Integrity and Induces Inflammation in a Gut-on-Chip Model},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17020089}
}
EUVIMED